BVF Partners ZYME Position
Active6-Fund ConvergenceBVF Partners held their position in Zymeworks Inc. (ZYME) in Q4 2025, holding $103.7M worth of shares across 3,938,641 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
ZYME is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Futibatinib in 442 days (Jun 30, 2027), making the timing of BVF's position particularly relevant.
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Full company profile →Short Interest
8.2%
5.4 days to cover
BVF Partners ZYME Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 3,938,641 | — | $103.7M |
| Q3 2025 | Decreased | 3,938,641 | -370,294 | $67.3M |
| Q2 2025 | Held | 4,308,935 | — | $54.1M |
| Q1 2025 | Held | 4,308,935 | — | $51.3M |
| Q4 2024 | Decreased | 4,308,935 | -299,000 | $63.1M |
| Q3 2024 | Decreased | 4,607,935 | -1,262,065 | $57.8M |
| Q2 2024 | Held | 5,870,000 | — | $50.0M |
| Q1 2024 | Held | 5,870,000 | — | $61.8M |
| Q4 2023 | Held | 5,870,000 | — | $61.0M |
| Q3 2023 | Held | 5,870,000 | — | $37.2M |
| Q2 2023 | Held | 5,870,000 | — | $50.7M |
| Q1 2023 | New | 5,870,000 | +5,870,000 | $53.1M |
Frequently Asked Questions
Does BVF Partners own ZYME?
Yes. As of Q4 2025, BVF Partners holds 3,938,641 shares of Zymeworks Inc. (ZYME) valued at $103.7M. This data comes from their SEC 13F filing.
How many hedge funds own ZYME?
6 specialist biotech hedge funds currently hold ZYME, including EcoR1 Capital, Perceptive Advisors, Redmile Group and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy ZYME?
BVF Partners's position in ZYME was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's ZYME position increasing or decreasing?
BVF Partners held their ZYME position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ZYMECompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →